Sentences with phrase «cure research»

The center is directed by Warner C. Greene, MD, PhD, who is also co-director of the UCSF - Gladstone Center for AIDS Research, as well as a principal investigator and member of the board of directors of the amfAR Institute for HIV Cure Research at UCSF.

Findings reveal a second target for cure research.

Hepner told A Sweet Life that she wants to show «the Herculean efforts behind most cure research.»

Born with HIV, she joined the community advisory board for the Fred Hutch - based cure research group defeatHIV to «see if I could get other women involved and make sure they have a voice.»

«Our ultimate goal is to allow infected individuals to eventually discontinue antiretroviral therapy,» said Greene, who is also co-director of the UCSF - Gladstone Center for AIDS Research and principal investigator with the amfAR Institute for HIV Cure Research at UCSF.

Bill Hall, a Tlingit from Southeast Alaska, serves on the community advisory board of the Fred Hutch - based defeatHIV cure research group.

The National Institutes of Health (NIH) funded this program as part of the Martin Delaney Collaboratories for HIV Cure Research initiative.

Watch this short video to see how your donation supports T1D cure research.

Deepak Srivastava, MD - President, Gladstone Institutes Steve Finkbeiner, MD, PhD - Director, Center of Systems and Therapeutics Warner C. Greene, MD, PhD - Director, Center for HIV Cure Research Lennart Mucke, MD - Director, Gladstone Institute of Neurological Disease Katherine S. Pollard, PhD - Director, Gladstone Institute of Data Science and Biotechnology

PHILADELPHIA --(April 18, 2018)-- An international team focused on HIV cure research spearheaded by The Wistar Institute in collaboration with the University of Pennsylvania and Vall d'Hebron Research Institute (VHIR) in Barcelona, Spain, established that the CD32 molecule is not a preferential biomarker to identify HIV silent reservoirs within the immune system of patients undergoing antiretroviral therapy (ART), as proposed by a recent landmark study.

The Gladstone Center for HIV Cure Research seeks to build upon the past success of the Gladstone Institute of Virology and Immunology, but with a singular research focus: to identify, reduce, and control latent HIV reservoirs to allow infected individuals to eventually discontinue antiretroviral therapy.

The obvious implication, which turns out to be right on the money, is that Delos wants to use Dr. Ford and Westworld's AI technology to allow him to put his actual mind in a host body — one that won't break down on him after he contracts the illness whose cure research he defunded years ago.

I'd like them to understand the Herculean efforts behind most cure research and to know that they have good reason to keep hoping.»

«Researchers discuss challenges, successes of HIV cure research in science.»

«HIV cure research: Scientists create two - headed protein to deplete HIV reservoir.»

In the Science perspective, the researchers discuss the gains they have made in understanding latency over the past five years and the challenges that remain as the team of academic and industry investigators — from UNC, Duke University, Merck, GlaxoSmithKline, the University of California at San Diego, Emory University, MacroGenics, and other institutions — embark on the next steps in HIV cure research.

The authors also detail how bnAbs could change HIV treatment and cure research.

Immunologist and molecular virologist David Margolis is at the forefront of HIV cure research.

He co-chairs a scientific working group on HIV cure research that is sponsored by the International AIDS Society.

«We are proposing an innovative and comprehensive approach to fill a major gap in HIV cure research,» said project lead Warner C. Greene, MD, PhD, director of the Gladstone Institute of Virology and Immunology and co-director of the UCSF - Gladstone Center for AIDS Research.

At the Catalyst for a Cure benefit gala on January 31, 2013, the four principal scientists in the second consortium outlined the importance of their project and the benefits of the Catalyst for a Cure research model, pooling together individuals from different institutions providing unique skills and knowledge.

March 14, 2012, San Francisco — Glaucoma Research Foundation (GRF) announced today that it will double its Catalyst for a Cure research consortium to eight research scientists from prestigious universities across the United States.

The expanded Catalyst for a Cure research consortium includes David Calkins, PhD, Vanderbilt University; Alfredo Dubra, PhD, Medical College of Wisconsin; Jeffrey Goldberg, MD, PhD, Bascom Palmer Eye Institute; Philip Horner, PhD, University of Washington; Andrew Huberman, PhD, University of California, San Diego; Nicholas Marsh - Armstrong, PhD, Johns Hopkins University; Vivek Srinivasan, PhD, Massachusetts General Hospital; and Monica Vetter, PhD, University of Utah.

Recently, Glaucoma Research Foundation expanded its novel initiative to advance glaucoma research through a collaborative approach by bringing together a second Catalyst for a Cure research team.

The following video provides a summary of Catalyst for a Cure research and an update on research progress by the team during the past year.

In addition, investigators from the Division of Experimental Medicine at UC San Francisco, the amfAR Institute for HIV Cure Research, and the Blood Systems Research Institute actively collaborate with this center.

The research project was supported by the National Institutes of Health (R01 AI083139, U19 AI096113, 1DP1DA038043, T32 GM007175), the UCSF — Gladstone Center for AIDS Research (P30 AI027763), the amfAR Institute for HIV Cure Research (109301), and the James B. Pendleton Charitable Trust.

They also want us to understand what's involved in cure research and why it's a laborious and intricate process.

This is the first clinical trial of its kind and The Human Trial is the first film to take us backstage into the world of cure research: the formidable obstacles and grinding effort, the complexity of the disease and the science, what it takes to harvest cells, regulatory rules and the $ 5 billion plus it typically takes to bring a drug to market.

This work was supported by the National Institutes of Health (R01AI127219, DP1DA036502) and the amfAR Institute for HIV Cure Research.

A Sweet Life notes that this «is the first clinical trial of its kind and The Human Trial is the first film to take us backstage into the world of cure research.»

This article is excerpted from a May 14, 2009 GRF President's Teleconference with members of our Catalyst Circle, in which Philip Horner, PhD of the University of Washington reports on recent discoveries by the Catalyst For a Cure research consortium.

As a group, the Catalyst For a Cure research team was able to show that the primary cell that's affected in glaucoma, the retinal ganglion cell, does not die early in the stages of the disease.

The team members, all experts in the field of HIV cure research, have a well - established record of working collaboratively and were the sole winners of amfAR's national, invitation - only funding competition.

amfAR, The Foundation for AIDS Research, today announced the establishment of the amfAR Institute for HIV Cure Research, an innovative collaborative enterprise based at the University of California, San Francisco.

With $ 20 million over five years, the amfAR Institute for HIV Cure Research will support the work of scientists at UC San Francisco (UCSF), the Gladstone Institute for Virology and Immunology (GIVI), the Blood Systems Research Institute (BSRI) and other academic partners who are at the forefront of the effort to cure AIDS, rather than simply treating it as a chronic disease.

Sunday's «birthday» celebration, a tradition among transplant cancer survivors, capped a day - long workshop on HIV cure research on the eve of a major HIV scientific meeting, the annual Conference on Retroviruses and Opportunistic Infections, or CROI, being held in Seattle.

The amfAR Institute for HIV Cure Research is the centerpiece of the foundation's $ 100 million investment strategy to achieve a cure for HIV, which infects more than 35 million people worldwide, according to the World Health Organization.

The new centers are the Center for Cell Circuitry, the Center for HIV Cure Research, and the Center for Systems and Therapeutics.

Collaborators for this new center include investigators at Gladstone, UCSF, the amfAR Institute for HIV Cure Research, and the Blood Systems Research Institute.

What motivates me as a scientist is knowing that because of the Catalyst for a Cure my research is going to have an impact on patients.

This research project was funded by the UCSF — Gladstone Center for AIDS Research (P30 AI027763), the amfAR Institute for HIV Cure Research (109301), the California HIV / AIDS Research Program (F13 - 373GI - 316), the James B. Pendleton Charitable Trust, as well as grant support from the Collaboratory of AIDS Researchers for Eradication (U19 AI096113) and the National Institutes of Health (RO1AI083139, RO1 DA043142, and P50 GM082250).

Collaborators will also include investigators from the Division of Experimental Medicine at UC San Francisco, the amfAR Institute for HIV Cure Research, and the Blood Systems Research Institute.

The new Center for HIV Cure Research, directed by Warner C. Greene, MD, PhD, seeks to build upon the past success of the Gladstone Institute of Virology and Immunology, but with a singular research focus: to identify, reduce, and control latent HIV reservoirs.

The all - day meeting showcased the work of more than 100 experts from academia, federal and regulatory agencies, government research agencies, pharmaceutical and biotech industry, and patient advocacy community who have worked together over the past several months to prepare draft consensus recommendations on how to address the regulatory issues around HIV cure research.

Among other things, it features articles on new developments in HIV cure research, recent studies that show promise but also possible pitfalls of using adenovirus vectors in HIV vaccine candidates, and the funding crisis at the Global Fund to Fight AIDS, Tuberculosis and Malaria.

IAVI Report caught up with husband and wife team Robert and Janet Siliciano from Johns Hopkins University School of Medicine in Baltimore, Maryland, at this week's Keystone Symposium to get their initial impressions of the meeting and their take on the status of HIV cure research.

The expanded Catalyst for a Cure research consortium includes David Calkins, PhD, Vanderbilt University; Alfredo Dubra, PhD, Medical College of Wisconsin; Jeffrey Goldberg, MD, PhD, Shiley Eye Center, University of California San Diego; Philip Horner, PhD, University of Washington; Andrew Huberman, PhD, University of California San Diego; Nicholas Marsh - Armstrong, PhD, Johns Hopkins University; Vivek Srinivasan, PhD, University of California Davis; and Monica Vetter, PhD, University of Utah.